Hogan Lovells appoints Gary Veron
Gary Veron has joined Hogan Lovells’ government regulatory practice as a partner in the Washington, DC, office. He joins from Sidley Austin, where he served as counsel in the food and drug practice.
Veron focuses his practice on food and drug law with an emphasis on the intersection of regulatory law and intellectual property law for pharmaceutical and biotechnology products. He represents pharmaceutical, biotechnology and medical device companies on a range of US Food and Drug Administration (FDA) regulatory and enforcement matters.
His practice over the past 10 years has focused primarily on the Hatch-Waxman Act and lifecycle management issues. He is a frequent advocate before the FDA on behalf of manufacturers of pioneer and brand-name pharmaceuticals. In a recent complex petition matter, Veron won a significant ruling, limiting the ability of generic drug applicants to avoid a pioneer company’s exclusivity rights.
Veron is a registered patent attorney and before practising law served as a technology development specialist in the US National Institutes of Health (NIH). He also served as legislative counsel to the Maryland General Assembly.
He holds a JD from the University of Virginia School of Law and a BS in biology from Virginia Polytechnic Institute.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
Judgments handed down from the People’s Court all over the country will be available online from 1 January 2014, as part of the initiative by the Supreme People’s Court of China (SPC) to increase judicial transparency.
An issue that comes up fairly regularly in redundancy selection is whether employers must consider all employees in similar roles or whether they can opt for a ‘pool of one’.
Analysis from The Lawyer
The Lawyer’s latest Top 50 litigation firms list shows that business for dispute specialists is roaring along while new in-depth detail reveals the winning strategies
The Russian legal market faces a new era as the government opens the door to greater business transparency, but not everything is open to scrutiny